Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
I thought I knew the night sky, but what I saw from the Canary Islands left me speechless - 25 Home EV Chargers for Proficient and Solid Charging
- 3Famous Rough terrain Vehicles for 2024
- 4The Best Web-based Courses for Ability Advancement
- 5Can ICE agents detain U.S. citizens? What powers do they have to arrest people? Your most common questions answered.
- Hungary's 'water guardian' farmers fight back against desertification
- Holiday travel: Best days to hit the road as 110 million Americans expected to drive over Christmas and New Year's
- Vote In favor of Your Favored Web-based Visual depiction Administration
- January’s full wolf supermoon and the Quadrantid meteor shower will start off the new year
- Colombia's military rescues 6 siblings who hid in the rainforest to escape from a rebel group
- Astronomers may have spotted the 1st known 'superkilonova' double star explosion
- Germany's Bundestag extends two armed forces missions abroad
- Atorvastatin recall may affect hundreds of thousands of patients – and reflects FDA’s troubles inspecting medicines manufactured overseas
- China’s new condom tax will prove no effective barrier to country’s declining fertility rate
